Blood serum levels of PACAP and migraine onset: A systematic review and meta‐analysis of observational studies
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14711 ↗At a glance
Metaanalyse in Headache: The Journal of Head and Face Pain, 2024. Written by Guoliang Zhu and 2 co-authors. Institution: Department of Neurology, The Affiliated Hospital of Yunnan University, Kunming, P. R. China. Major MEDLINE topics: Migraine Disorders, Observational Studies as Topic, Pituitary Adenylate Cyclase-Activating Polypeptide. Cited 4 times so far (Crossref); 52 references.
Abstract (original language)
Objective
We conducted a systematic review and meta‐analysis to explore the relationship between blood pituitary adenylate cyclase‐activating polypeptide (PACAP) levels and migraine.
Background
PACAP is involved in the onset of migraine, but the results from clinical studies on PACAP level variations across different periods of migraine are conflicting.
Methods
We systematically searched for observational studies that reported PACAP levels in people with migraine and non‐migraine controls published in English from the PubMed, Web of Science, and Ovid electronic databases, or in Chinese from the Chinese National Knowledge Infrastructure and the WanFang Med database. The Newcastle–Ottawa Quality Assessment Scale was used to assess the quality of the included studies. The quality of evidence for each outcome was assessed according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines.
Results
Of the 514 identified studies, 8 were eligible for inclusion. There was a “very low” level of evidence suggesting that the PACAP level is negatively correlated with migraine disease duration in adults with migraine (summary = −0.35, 95% confidence interval [CI] −0.49 to −0.22) and that the PACAP is higher in people with migraine during the ictal period than in the interictal period (standardized mean difference = 0.41, 95% CI 0.17 to 0.66) for both adults and children with migraine. Adult patients with episodic migraine (weighted mean difference [WMD] = −9.58 pg/mL, 95% CI −13.41 to −5.75 pg/mL) or chronic migraine (WMD = −10.93 pg/mL, 95% CI −15.57 to −6.29 pg/mL) had lower blood PACAP levels than non‐migraine controls during the interictal period, supported by a “low” or “very low” quality of evidence, respectively, according to the GRADE rules.
Conclusion
There is a very low certainty of evidence suggesting that the PACAP level is negatively correlated with migraine disease duration of adults with migraine and it varies greatly among different periods of migraine of both adults and children with migraine.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, The Affiliated Hospital of Yunnan University, Kunming, P. R. China.
- School of Clinical Medicine, Dali University, Dali, P. R. China.
- Department of Neurology, West China Hospital, Sichuan University, Chengdu, P. R. China.
ORCID profiles: Guoliang Zhu, Miao Wang, Fanyi Kong
Cite
APA
Zhu, G., Wang, M., & Kong, F. (2024). Blood serum levels of PACAP and migraine onset: A systematic review and meta‐analysis of observational studies. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14711
Vancouver
Zhu G, Wang M, Kong F. Blood serum levels of PACAP and migraine onset: A systematic review and meta‐analysis of observational studies. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14711
BibTeX
@article{Zhu2024,
author = {Zhu, Guoliang and Wang, Miao and Kong, Fanyi},
title = {Blood serum levels of PACAP and migraine onset: A systematic review and meta‐analysis of observational studies},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14711}
}
EUVIMED